Form 4: Cidara Therapeutics CFO Acquires Stock Options
SEC Form 4 Filing
Preetam Shah, CFO of Cidara Therapeutics, reports the acquisition of stock options.
Summary
- On September 30, 2024, Preetam Shah, the Chief Financial Officer of Cidara Therapeutics, acquired 130,087 employee stock options.
- These options have an exercise price of $10.75.
- The options vest in 36 equal monthly installments starting from September 30, 2024, and expire on September 29, 2034.
- Following this transaction, Shah directly owns 130,087 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a standard executive compensation practice and doesn't inherently indicate positive or negative sentiment about the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, indicating a change in beneficial ownership of securities by a company insider. It's a routine part of executive compensation and doesn't necessarily indicate a major shift in the company's prospects.
Stakeholder Impact
- The granting of stock options aligns the CFO's interests with those of the shareholders, as the value of the options increases if the company's stock price increases.
Key Dates
| Date | Description |
|---|---|
| 09/30/2024 | Date of earliest transaction and vesting commencement date for the stock options. |
| 09/29/2034 | Expiration date of the stock options. |
| 10/02/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.